PubMed Health⌕ Search

Biomedical subjects

Harold L Dauerman

Publications and source records attributed to Harold L Dauerman.

27 records · Page 2Linked to original sources
PubMed2003

Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting.

Patients with diabetes are at increased risk for adverse events after coronary stenting, perhaps reflecting a pro-inflammatory state. To characterize the inflammatory response to coronary stenting in patients with and without diabetes, blood samples were obtained from 75 patients before stenting and 10 minutes, 1 hour, and 24 hours later. C-reactive protein (CRP, microg/ml), interleukin (IL)-6 (pg/ml), IL-1 receptor antagonist (pg/ml), and soluble CD40 ligand (ng/ml) were assayed in each sample by enzyme-linked immunosorbent assay. Concentration changes after stenting were identified by repeated-measures analysis of variance. Multivariate analysis was performed to delineate independent predictors of increased concentrations of inflammation markers. Overall, 88% of patients had acute coronary syndromes; 36% had elevated markers of cardiac injury. The preprocedural concentrations of CRP in those with diabetes were more than twice as high as those in patients without diabetes. Two independent predictors of elevated preprocedural CRP concentrations were diabetes (odds ratio 3.95, 95% confidence interval 1.17 to 13.4) and a cardiac marker-positive acute coronary syndrome (odds ratio 3.70, 95% confidence interval 1.22 to 11.2). Preprocedural concentrations of IL-6, IL-1 receptor antagonist, and soluble CD40 ligand tended to be greater in patients with diabetes. The increase in CRP after stenting was much greater for patients without diabetes compared with that in patients with diabetes such that the apparent intensity of inflammation after 24 hours was similar in those with and without diabetes. Thus, patients with and without diabetes exhibit different inflammatory responses to stenting, reflecting the lower preprocedural inflammation in those without diabetes versus those with diabetes.

Acute Disease↗
PubMed2003

Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization.

Both pharmacologic and mechanical approaches designed to limit infarct size by recanalization of infarct-related arteries have reduced mortality associated with ST-segment elevation myocardial infarction (STEMI). Early efforts to combine the two were attenuated because of complications encountered. Primary percutaneous coronary intervention (PCI) and thrombolysis became viewed as alternative rather than complementary modalities. Time to recanalization and adequacy of restoration of perfusion were found to be pivotal determinants of a favorable outcome with either approach. Because pharmacologic intervention can be initiated immediately in virtually any hospital, it is a promising initial step. Because PCI proffers more complete recanalization, it may be a particularly salutary initial or subsequent step. Because of unavoidable delay often confronting implementation of PCI, optimal advantage may accrue from the use of both approaches in combination. We seek to emphasize the potential synergy by referring to the combined approach as "pharmacoinvasive recanalization" rather than by the conventional term "facilitated PCI." Virtually all patients with STEMI can benefit from prompt, sustained, and complete coronary recanalization. Thus, investigations focusing on identification of pharmacologic regimens that can safely initiate recanalization as early as possible, minimize bleeding, and broaden the temporal window available for efficacy of subsequent, optimally timed PCI should provide particularly valuable information.

Combined Modality Therapy↗
PubMed2003

Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response.

BACKGROUND: Inflammation after coronary stenting presages adverse outcomes after percutaneous coronary intervention (PCI). While changes in inflammatory markers have been defined 24-72 hours after PCI, potential changes during the first few hours have not. This study was designed to determine if a systemic inflammatory response could be measured within the first hour after stenting. METHODS: Patients (n = 25) undergoing coronary stenting, with predominantly (n = 23) acute coronary syndromes were enrolled prospectively in this registry. Blood samples were collected before PCI, and 10 minutes, 1 hour and 18-24 hours later. No patient received a glycoprotein IIb-IIIa inhibitor. Concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), and interleukin-1 receptor antagonist (IL-1Ra) and soluble CD40 ligand (sCD40L) were measured using ELISA. RESULTS: CRP and sCD40L did not change in the first hour after stenting. By contrast, IL-6 increased in the first hour (before = 7.6 +/- 7.7 pg/ml, 1 hour = 12 +/- 12 pg/ml; p < 0.001). The concentration of IL-1Ra tended to be greater after 1 hour (before = 426 +/- 261 pg/ml, 1 hour = 511 +/- 406 pg/ml; p = 0.11). Increase in IL-1Ra was apparent only in female subjects (p = 0.004 for the difference in trend between the two genders). A correlation was not observed between the increase in IL-6 at 1 hour and the increase in CRP at 24 hours (r = -0.21). CONCLUSIONS: In patients undergoing coronary stenting, increase in IL-6 can be detected 1 hour after PCI, and thus IL-6 may be an early initiator of the systemic inflammatory response to stenting.

Aged↗
PubMed2003

Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience.

OBJECTIVES: The objective of this study was to determine the characteristics and hospital mortality rate for elderly patients in cardiogenic shock undergoing emergent percutaneous coronary intervention (PCI). BACKGROUND: Early revascularization for patients with acute myocardial infarction complicated by cardiogenic shock is recommended for patients < 75 years of age. This age-restricted recommendation is based upon evidence that elderly shock patients undergoing early revascularization have extremely high hospital mortality rates. The real world mortality rate for elderly shock patients undergoing emergent PCI has not been determined. METHODS: We examined a decade-long experience in our prospective registry of consecutive PCIs in Northern New England to assess the generalizability of these findings. Characteristics and hospital mortality were compared for elderly ( 75 years old) versus non-elderly (< 75 years old) patients. Predictors of hospital survival were identified using multivariate logistic regression. RESULTS: From 1990 to 2000, a total of 310 out of 52,418 patients (0.59%) had PCI for cardiogenic shock, twenty-four percent of whom were elderly. Procedural characteristics were similar between the 2 groups. Independent predictors of mortality for both groups were older age and the absence of collaterals; during the stent era (1997 2000), significant predictors were lack of stent placement and diabetes mellitus. The mortality rate for elderly shock patients undergoing PCI was 46%, which is significantly less than previously reported in randomized clinical trials. CONCLUSION: Real world selection of elderly shock patients for PCI is possible with mortality rates far less than seen in randomized trials.

Age Factors↗
PubMed2002

Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.

Randomized clinical trials have demonstrated a reduction in mortality with early revascularization of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock, and recent single-center studies have particularly suggested further benefit for coronary stenting. The purpose of this study was to examine the use of revascularization and coronary stenting for patients with shock from a multicenter, international perspective. Patients with AMI complicated by cardiogenic shock (n = 583) who enrolled between April 1999 and June 2001 were prospectively identified from the large, multinational, observational Global Registry of Acute Coronary Events. We examined the use of coronary reperfusion strategies, adjunctive therapy, and hospital mortality in this group of patients. Cardiac catheterization (52%) and revascularization (43%) were performed in approximately half of the cardiogenic shock patients. Elderly patients (age >/=75 years) comprised 40% of the shock cohort. Regional differences were seen in the use of revascularization, adjunctive medical therapy, and type of revascularization used (coronary stenting). Total hospital mortality was 59%, but case fatality rates ranged from 35% for patients who underwent coronary stenting to 74% for patients who did not undergo any cardiac catheterization. Percutaneous coronary intervention with coronary stenting was the most powerful predictor of hospital survival (odds ratio 3.99, 95% confidence interval 2.41 to 6.62). Thus, cardiogenic shock continues to be a devastating complication of AMI, and relative underuse of a revascularization strategy may be related to the large proportion of elderly patients in this population. In this multinational registry study, coronary stenting was the most powerful independent predictor of hospital survival.

Aged↗
PubMed2002

Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.

BACKGROUND: Previous studies have demonstrated a prolongation of activated clotting times (ACT) with abciximab administration during percutaneous coronary interventions (PCI). The impact of the short acting glycoprotein (GP) IIb-IIIa inhibitor, eptifibatide, on ACT measurements has not been studied. METHODS: Seventy consecutive patients undergoing PCI in the setting of eptifibatide administration were prospectively enrolled in a single center study. Eptifibatide was administered as two 180 microg/kg boluses 10 minutes apart followed by a continuous infusion of 2.0 microg/kg/min. In 15 patients (Group I), the initial eptifibatide and heparin boluses were separated by 5 minutes, and ACT's were assessed after each bolus as well as at 3 subsequent time points. In 55 patients (Group II), an ACT level was drawn 10 minutes after the initial heparin/eptifibatide bolus and 20 minutes following the second eptifibatide bolus. Two different ACT measuring devices--CoaguChek Pro DM and Hemochron 801--were used to examine the impact of eptifibatide on ACT values. RESULTS: The devices differed in the reproducibility of their measurements, but the overall trends were consistent with both devices. The ACT value was unchanged after the initial eptifibatide bolus (with a delta of 0.6 seconds by CoaguChek Pro DM and 4.2 seconds by Hemochron). While the ACT value rose significantly after the heparin bolus, the second eptifibatide bolus did not result in any further rise in ACT values. CONCLUSIONS: Unlike abciximab, eptifibatide does not significantly prolong the ACT in patients undergoing PCI. This may have implications regarding the need for separate heparin dosing algorithms for patients undergoing PCI in the setting of different GPIIb-IIIa inhibitors.

Angioplasty, Balloon, Coronary↗
PubMed2002

Use of the invasive management strategy for patients with non-Q-wave myocardial infarction: an observational database report from the Worcester Heart Attack Study.

BACKGROUND: Recent randomized clinical trials have suggested a benefit of an invasive management strategy in patients with acute coronary syndromes. However, the broader use and impact of the invasive management approach has not been established for patients with acute coronary syndromes beyond the relatively narrow patient populations studied in randomized, clinical trials. METHODS: Residents of the Worcester, Mass, area who were hospitalized with non-Q-wave acute myocardial infarction (AMI) at all area hospitals in 5 annual periods between 1990 and 1997 comprised the sample of interest (n = 2436). We examined the extent of use of an invasive versus a conservative strategy for hospital management, occurrence of clinical complications, and hospital mortality in patients with non-Q-wave AMI. RESULTS: An invasive approach to hospital management was used in only 30% of patients with non-Q-wave AMI, although there was an increase over time in the use of an invasive treatment strategy (18% in 1990 vs 33% in 1997). Factors associated with use of the invasive strategy were younger age, male sex, development of cardiogenic shock, as well as adjunctive medical treatment. Overall hospital mortality was high at 12%. Use of the invasive approach, aspirin, nitrates and beta-blockers were associated in logistic regression modeling with significant improvements in survival. CONCLUSIONS: An invasive approach to hospital management of non-Q-wave AMI was used infrequently in this population-based cohort during the 1990s.

Age Factors↗